Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.

James E Wild,Stefan Grond, Brigitte Kuperwasser,Jane Gilbert,Bettyanne McCann,Bernd Lange,Achim Steup,Thomas Häufel,Mila S Etropolski,Christine Rauschkolb,Robert Lange

PAIN PRACTICE（2010）

引用 140|浏览11

暂无评分

摘要

Tapentadol ER (100 to 250 mg bid) was associated with better gastrointestinal tolerability than oxycodone HCl CR (20 to 50 mg bid) and provided sustainable relief of moderate to severe chronic knee or hip osteoarthritis or low back pain for up to 1 year.

查看译文

关键词

analgesics,opioid,low back pain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要